
                                SEQUENCE LISTING

<110> Soares, Christopher J.

<120> CGRP AGONIST PEPTIDES
  

<130> CSOAR.002WO

<150> 61/860,244          
<151> 2013-07-30  

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 32
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 1
Ala Cys Asp Thr Ala Thr Cys Val Leu Gly Arg Leu Ser Gln Glu Leu
 1               5                  10                  15      
His Arg Leu Gln Thr Tyr Pro Arg Thr Asn Val Gly Ser Lys Ala Phe
            20                  25                  30          


<210> 2
<211> 31
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 2
Ala Cys Asp Thr Ala Thr Cys Val Leu Gly Arg Leu Ser Gln Glu Leu
 1               5                  10                  15      
His Arg Leu Gln Thr Tyr Pro Thr Asn Val Gly Ser Lys Ala Phe
            20                  25                  30      


<210> 3
<211> 31
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 3
Cys Asp Thr Ala Thr Cys Val Leu Gly Arg Leu Ser Gln Glu Leu His
 1               5                  10                  15      
Arg Leu Gln Thr Tyr Pro Arg Thr Asn Val Gly Ser Lys Ala Phe
            20                  25                  30      


<210> 4
<211> 30
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 4
Cys Asp Thr Ala Thr Cys Val Leu Gly Arg Leu Ser Gln Glu Leu His
 1               5                  10                  15      
Arg Leu Gln Thr Tyr Pro Thr Asn Val Gly Ser Lys Ala Phe
            20                  25                  30  


<210> 5
<211> 32
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 5
Ala Cys Asp Thr Ala Thr Cys Met Leu Gly Arg Tyr Thr Gln Asp Phe
 1               5                  10                  15      
Asn Arg Phe His Thr Phe Pro Arg Thr Asn Val Gly Ser Lys Ala Phe
            20                  25                  30          


<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<220> 
<221> VARIANT        
<222> 1
<223> Xaa = Ala or Cys or is not present

<220> 
<221> VARIANT        
<222> 2
<223> Xaa = Cys, Ser or Gly, provided that at least one
      of X1 and X2 is Cys and only one of X1 or X2 is
      Cys

<220> 
<221> VARIANT        
<222> 3
<223> Xaa = Asp or Asn

<220> 
<221> VARIANT        
<222> 5
<223> Xaa = Ala or Ser and wherein the terminal Cys of
      X1 is capable of forming a disulfide bridge with
      the Cys residue in X1 or X2

<400> 6
Xaa Xaa Xaa Thr Xaa Thr Cys
 1               5          


<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Val or Met

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Lys or Tyr

<220> 
<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Ser or Thr

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Asp or Glu


<220> 
<221> VARIANT        
<222> 9, 12
<223> Xaa = Phe or Lys


<220> 
<221> VARIANT        
<222> (10)...(10)
<223> Xaa = His or Asn


<220> 
<221> VARIANT        
<222> (13)...(13)
<223> Xaa = His or Gln


<220> 
<221> VARIANT        
<222> (15)...(15)
<223> Xaa = Phe or Tyr

<400> 7
Xaa Lys Gly Arg Xaa Xaa Gln Xaa Xaa Xaa Arg Xaa Xaa Thr Xaa
 1               5                  10                  15  


<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<220> 
<221> VARIANT        
<222> 2
<223> Xaa = Arg or Gln

<220> 
<221> VARIANT        
<222> 4
<223> Xaa = Asn or Ala

<400> 8
Pro Xaa Thr Xaa Val Gly Ser Lys Ala Phe
 1               5                  10  


<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 9
Ala Cys Asp Thr Ala Thr Cys
 1               5          


<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic polypeptide

<400> 10
Pro Arg Thr Asn Val Gly Ser Lys Ala Phe
 1               5                  10  

